Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 9;38(28):4362-4373.
doi: 10.1016/j.vaccine.2020.02.073. Epub 2020 Apr 28.

Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019

Sami L Gottlieb  1 , Francis Ndowa  2 , Edward W Hook 3rd  3 , Carolyn Deal  4 , Laura Bachmann  5 , Laith Abu-Raddad  6 , Xiang-Sheng Chen  7 , Ann Jerse  8 , Nicola Low  9 , Calman A MacLennan  10 , Helen Petousis-Harris  11 , Kate L Seib  12 , Magnus Unemo  13 , Leah Vincent  4 , Birgitte K Giersing  14 ; Gonococcal Vaccine PPC Expert Advisory Group
Affiliations

Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019

Sami L Gottlieb et al. Vaccine. .

Abstract

Renewed interest in developing vaccines against Neisseria gonorrhoeae has been sparked by the increasing threat of gonococcal antimicrobial resistance (AMR) and growing optimism that gonococcal vaccines are biologically feasible. Evidence suggests serogroup B Neisseria meningitidis vaccines might provide some cross-protection against N. gonorrhoeae, and new gonococcal vaccine candidates based on several approaches are currently in preclinical development. To further stimulate investment and accelerate development of gonococcal vaccines, greater understanding is needed regarding the overall value that gonococcal vaccines might have in addressing public health and societal goals in low-, middle-, and high-income country contexts and how future gonococcal vaccines might be accepted and used, if available. In January 2019, the World Health Organization (WHO) convened a multidisciplinary international group of experts to lay the groundwork for understanding the potential health, economic, and societal value of gonococcal vaccines and their likely acceptance and use, and for developing gonococcal vaccine preferred product characteristics (PPCs). WHO PPCs describe preferences for vaccine attributes that would help optimize vaccine value and use in meeting the global public health need. This paper describes the main discussion points and conclusions from the January 2019 meeting of experts. Participants emphasized the need for vaccines to control N. gonorrhoeae infections with the ultimate goals of preventing adverse sexual and reproductive health outcomes (e.g., infertility) and reducing the impact of gonococcal AMR. Meeting participants also discussed important PPC considerations (e.g., vaccine indications, target populations, and potential immunization strategies) and highlighted crucial research and data needs for guiding the value assessment and PPCs for gonococcal vaccines and advancing gonococcal vaccine development.

Keywords: Gonococcal vaccines; Gonorrhea; Neisseria gonorrhoeae; Sexually transmitted infections; Vaccines.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Drs Gottlieb, Ndowa, Hook, Deal, Bachmann, Abu-Raddad, Chen, Low, MacLennan, Petousis-Harris, Unemo, Vincent, and Giersing report no conflicts of interest. Dr Jerse’s laboratory has conducted or is conducting research with the following companies under cooperative research and development agreements (CRADAs) or subcontracts to National Institutes of Health (NIH) grants: Chiron Corporation; Discuva, Ltd; GlaxoSmithKline; Microbiotx, Inc; The Population Council; Reoxcyn Discoveries Group; Tetraphase, Inc; Topcaid; VenatoRx; and Yaso Therapeutics. Dr Seib reports a brief consultancy with GlaxoSmithKline to provide expert advice on gonorrhoea in Australia, which occurred after the WHO Consultation in January 2019.

References

    1. Rowley J., Vander Hoorn S., Korenromp E., Low N., Unemo M., Abu-Raddad L.J. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548–562. - PMC - PubMed
    1. Unemo M., Lahra M.M., Cole M., Galarza P., Ndowa F., Martin I. World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. Sex Health. 2019 doi: 10.1071/SH19023. - DOI - PMC - PubMed
    1. World Health Organization. Global health sector strategy on sexually transmitted infections, 2016–2021; 2016 [updated 2016/07//]. Available from: https://www.who.int/reproductivehealth/publications/rtis/ghss-stis/en/.
    1. Wellcome Trust, Boston Consulting Group. Vaccines to tackle drug-resistant infections. An evaluation of R&D opportunities; 2016 [updated 2016]. Available from: https://vaccinesforamr.org/read-the-report/.
    1. Petousis-Harris H., Paynter J., Morgan J., Saxton P., McArdle B., Goodyear-Smith F. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390(10102):1603–1610. - PubMed

Publication types

Substances